BR0015811A - Tratamento de c nceres com aplidina - Google Patents

Tratamento de c nceres com aplidina

Info

Publication number
BR0015811A
BR0015811A BR0015811-9A BR0015811A BR0015811A BR 0015811 A BR0015811 A BR 0015811A BR 0015811 A BR0015811 A BR 0015811A BR 0015811 A BR0015811 A BR 0015811A
Authority
BR
Brazil
Prior art keywords
aplidine
treatment
tumor
cancers
nceres
Prior art date
Application number
BR0015811-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Glynn Thomas Faircloth
Chris Twelves
Luis Paz-Ares
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR0015811A publication Critical patent/BR0015811A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0015811-9A 1999-11-15 2000-11-15 Tratamento de c nceres com aplidina BR0015811A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers

Publications (1)

Publication Number Publication Date
BR0015811A true BR0015811A (pt) 2002-08-06

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015811-9A BR0015811A (pt) 1999-11-15 2000-11-15 Tratamento de c nceres com aplidina

Country Status (27)

Country Link
US (1) US20090298752A1 (https=)
EP (1) EP1229922B1 (https=)
JP (1) JP2003514025A (https=)
KR (1) KR100518986B1 (https=)
CN (1) CN1423564A (https=)
AT (1) ATE363910T1 (https=)
AU (1) AU780417B2 (https=)
BG (1) BG65381B1 (https=)
BR (1) BR0015811A (https=)
CA (1) CA2391502A1 (https=)
CY (1) CY1106825T1 (https=)
CZ (1) CZ302498B6 (https=)
DE (1) DE60035120T2 (https=)
DK (1) DK1229922T3 (https=)
ES (1) ES2288486T3 (https=)
HK (1) HK1045648B (https=)
HU (1) HUP0203906A2 (https=)
IL (1) IL149488A0 (https=)
MX (1) MXPA02004862A (https=)
NO (1) NO330719B1 (https=)
NZ (1) NZ518847A (https=)
PL (1) PL200922B1 (https=)
PT (1) PT1229922E (https=)
RU (1) RU2261104C2 (https=)
SI (1) SI1229922T1 (https=)
SK (1) SK287762B6 (https=)
WO (1) WO2001035974A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
IL155273A0 (en) 2000-10-12 2003-11-23 Pharma Mar Sa Pharmaceutical compositions comprising an aplidine compound
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
EP1620117A4 (en) * 2003-03-12 2009-07-29 Pharma Mar Sa IMPROVED ANTITUMORAL TREATMENTS
AU2004218883B2 (en) 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
ATE479432T1 (de) * 2006-11-03 2010-09-15 Nerviano Medical Sciences Srl Verfahren zur verabreichung einer antitumoralen verbindung
RU2360712C1 (ru) * 2007-10-02 2009-07-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения местно-распространенного неоперабельного рака прямой кишки
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
CA2717409A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved anticancer treatments
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
DE3684868D1 (de) * 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6030943A (en) * 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2405779A1 (en) * 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU1305302A (en) * 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
IL155273A0 (en) * 2000-10-12 2003-11-23 Pharma Mar Sa Pharmaceutical compositions comprising an aplidine compound
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
EP1620117A4 (en) * 2003-03-12 2009-07-29 Pharma Mar Sa IMPROVED ANTITUMORAL TREATMENTS
AU2004218883B2 (en) * 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
JP2006523214A (ja) * 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
BG65381B1 (bg) 2008-05-30
PL355335A1 (en) 2004-04-19
HK1045648A1 (en) 2002-12-06
CZ302498B6 (cs) 2011-06-15
KR20020064313A (ko) 2002-08-07
CN1423564A (zh) 2003-06-11
MXPA02004862A (es) 2003-01-28
US20090298752A1 (en) 2009-12-03
WO2001035974A3 (en) 2001-11-01
CZ20021697A3 (cs) 2003-02-12
SK6592002A3 (en) 2003-08-05
AU1402301A (en) 2001-05-30
BG106714A (en) 2003-02-28
SI1229922T1 (sl) 2008-04-30
PL200922B1 (pl) 2009-02-27
DE60035120D1 (de) 2007-07-19
ATE363910T1 (de) 2007-06-15
CY1106825T1 (el) 2012-05-23
EP1229922B1 (en) 2007-06-06
RU2261104C2 (ru) 2005-09-27
DE60035120T2 (de) 2008-01-31
HK1045648B (en) 2007-09-21
ES2288486T3 (es) 2008-01-16
NZ518847A (en) 2004-02-27
RU2002115864A (ru) 2004-01-20
HUP0203906A2 (en) 2003-03-28
DK1229922T3 (da) 2007-10-08
NO20022293D0 (no) 2002-05-14
NO20022293L (no) 2002-07-05
SK287762B6 (sk) 2011-09-05
PT1229922E (pt) 2007-09-12
NO330719B1 (no) 2011-06-20
WO2001035974A2 (en) 2001-05-25
IL149488A0 (en) 2002-11-10
KR100518986B1 (ko) 2005-10-06
EP1229922A2 (en) 2002-08-14
CA2391502A1 (en) 2001-05-25
AU780417B2 (en) 2005-03-17
JP2003514025A (ja) 2003-04-15

Similar Documents

Publication Publication Date Title
BR0015811A (pt) Tratamento de c nceres com aplidina
Westermark et al. Platelet-derived growth factor in autocrine transformation
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
AU5089799A (en) Drug complex for treatment of metastatic prostate cancer
PL354540A1 (en) Drugs for the treatment of malignant tumours
FI963283A0 (fi) 4-asemasta heterosyklyylillä substituoituja kinatsoliinijohdannaisia, menetelmiä niiden valmistamiseksi ja niiden käyttö syöpälääkkeinä
IL138330A0 (en) Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer
BR9407956A (pt) Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
AR033157A1 (es) Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
HUP9801746A2 (hu) Limfotoxin-alfa/béta komplexek és anti-limfotoxin-béta receptor antitestek mint tumorellenes szerek
NO975661L (no) Anvendelse av bis-1,2,4-triazoler for fremstilling av et medikament for behandling av cancer
TR200001687T2 (tr) Neopleasyo için N-benzil-3-indenilasetamid türevleri.
TR200103786T2 (tr) Güğüs kanserinin tehisi ve imünoterapisi için bileşikler ve bunların kullanımı
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
CY1106525T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ hCG ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ
NO20021011D0 (no) Fremgangsmåte og formulering for tumorremisjon og suppresjon av cancer
ATE332139T1 (de) 1,2,4-benzotriazin-oxide enthaltende zubereitungen
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
WO2000030587A3 (fr) INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES
NO20040973L (no) Anvendelse av 4-pyridylmetylftalaziner for kreftbehandling
Robbins Is high‐dose intensity intraarterial cisplatin chemoradiotherapy for head and neck carcinoma feasible?
BR9811147A (pt) Método de tratamento de câncer em hospedeiros mamìferos e processos de preparação de derivados de 13-deoxiantraciclina
NO20051444L (no) Medikament inneholdende disorazoler og derivater av disse for behandling av benigne og maligne tumorsykdommer.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA A CLASSIFICACAO DA INT. CL.: A61K 38/00.

Ipc: A61K 38/15 (2010.01), A61P 35/00 (2010.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.